ST段抬高型心肌梗死患者纤溶药物再灌注治疗的疗效与安全性比较:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入40项随机对照试验共128071例接受12种纤溶方案治疗的ST段抬高型心肌梗死患者。与加速输注阿替普酶联合肠外抗凝相比,链激酶和非加速输注阿替普酶的全因死亡风险显著增加;替奈普酶出血风险倾向于更低;加用糖蛋白IIb/IIIa抑制剂增加大出血风险。作者认为应优先考虑加速输注阿替普酶、替奈普酶和瑞替普酶,不鼓励加用糖蛋白IIb/IIIa抑制剂。
要点
- 与加速输注阿替普酶联合肠外抗凝相比,链激酶联合肠外抗凝的全因死亡风险显著增加(RR 1.14)。
- 非加速输注阿替普酶联合肠外抗凝的全因死亡风险也显著高于加速输注阿替普酶联合肠外抗凝(RR 1.26)。
- 替奈普酶方案的大出血风险倾向于低于其他方案(RR 0.79,95%CI 0.63-1.00)。
核心结论
- 不同纤溶方案作为STEMI再灌注治疗存在显著差异,作者认为应考虑加速输注阿替普酶、替奈普酶和瑞替普酶而非链激酶和非加速输注阿替普酶。
- 作者认为不鼓励在纤溶治疗基础上加用糖蛋白IIb/IIIa抑制剂。
研究设计与样本
- 基于系统评价的网状Meta分析,检索多个数据库自建库至2017年2月28日。
- 仅纳入比较纤溶药物(单独或联合辅助抗血栓治疗)与另一种纤溶药物、安慰剂或无治疗的随机对照试验,对象为成人STEMI患者。
- 仅纳入研究具有STEMI再灌注治疗获批适应证的药物:链激酶、替奈普酶、阿替普酶和瑞替普酶。
- 共纳入40项符合条件的研究,涉及128071例接受12种不同纤溶方案治疗的患者。
- 主要疗效结局为30-35天内全因死亡,主要安全性结局为大出血;研究注册于PROSPERO(CRD42016042131)。
主要发现
- 与加速输注阿替普酶联合肠外抗凝作为背景治疗相比,链激酶联合肠外抗凝的全因死亡风险显著增加(RR 1.14,95%CI 1.05-1.24)。
- 非加速输注阿替普酶联合肠外抗凝的全因死亡风险也显著高于加速输注阿替普酶联合肠外抗凝(RR 1.26,95%CI 1.10-1.45)。
- 加速输注阿替普酶、替奈普酶和瑞替普酶联合肠外抗凝作为背景治疗之间,死亡风险无显著差异。
- 对于大出血,替奈普酶方案与其他方案相比倾向于出血风险更低(RR 0.79,95%CI 0.63-1.00)。
- 在纤溶治疗基础上加用糖蛋白IIb/IIIa抑制剂,与加速输注阿替普酶联合肠外抗凝相比,大出血风险增加1.27-8.82倍(替奈普酶联合肠外抗凝加糖蛋白抑制剂RR 1.47,95%CI 1.10-1.98;瑞替普酶联合肠外抗凝加糖蛋白抑制剂RR 1.88,95%CI 1.24-2.86)。
关键数值与推荐
- 与加速输注阿替普酶联合肠外抗凝相比,链激酶联合肠外抗凝的全因死亡RR 1.14(95%CI 1.05-1.24)。
- 与加速输注阿替普酶联合肠外抗凝相比,非加速输注阿替普酶联合肠外抗凝的全因死亡RR 1.26(95%CI 1.10-1.45)。
- 替奈普酶方案与其他方案相比,大出血RR 0.79(95%CI 0.63-1.00)。
- 替奈普酶联合肠外抗凝加糖蛋白抑制剂与加速输注阿替普酶联合肠外抗凝相比,大出血RR 1.47(95%CI 1.10-1.98)。
- 瑞替普酶联合肠外抗凝加糖蛋白抑制剂与加速输注阿替普酶联合肠外抗凝相比,大出血RR 1.88(95%CI 1.24-2.86)。
临床怎么用
- 作者认为,STEMI再灌注治疗中应考虑加速输注阿替普酶、替奈普酶和瑞替普酶而非链激酶和非加速输注阿替普酶。
- 作者认为,不鼓励在纤溶治疗基础上加用糖蛋白IIb/IIIa抑制剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrinolytic therapy offers an alternative to mechanical reperfusion for ST-segment elevation myocardial infarction (STEMI) in settings where health-care resources are scarce. Comprehensive evidence comparing different agents is still unavailable. In this study, we examined the effects of various fibrinolytic drugs on clinical outcomes. METHODS: We did a network meta-analysis based on a systematic review of randomised controlled trials comparing fibrinolytic drugs in patients with STEMI. Several databases were searched from inception up to Feb 28, 2017. We included only randomised controlled trials that compared fibrinolytic agents as a reperfusion therapy in adult patients with STEMI, whether given alone or in combination with adjunctive antithrombotic therapy, against other fibrinolytic agents, a placebo, or no treatment. Only trials investigating agents with an approved indication of reperfusion therapy in STEMI (streptokinase, tenecteplase, alteplase, and reteplase) were included. The primary efficacy outcome was all-cause mortality within 30-35 days and the primary safety outcome was major bleeding. This study is registered with PROSPERO (CRD42016042131). FINDINGS: A total of 40 eligible studies involving 128 071 patients treated with 12 different fibrinolytic regimens were assessed. Compared with accelerated infusion of alteplase with parenteral anticoagulants as background therapy, streptokinase and non-accelerated infusion of alteplase were significantly associated with an increased risk of all-cause mortality (risk ratio [RR] 1·14 [95% CI 1·05-1·24] for streptokinase plus parenteral anticoagulants; RR 1·26 [1·10-1·45] for non-accelerated alteplase plus parenteral anticoagulants). No significant difference in mortality risk was recorded between accelerated infusion of alteplase, tenecteplase, and reteplase with parenteral anticoagulants as background therapy. For major bleeding, a tenecteplase-based regimen tended to be associated with lower risk of bleeding compared with other regimens (RR 0·79 [95% CI 0·63-1·00]). The addition of glycoprotein IIb or IIIa inhibitors to fibrinolytic therapy increased the risk of major bleeding by 1·27-8·82-times compared with accelerated infusion alteplase plus parenteral anticoagulants (RR 1·47 [95% CI 1·10-1·98] for tenecteplase plus parenteral anticoagulants plus glycoprotein inhibitors; RR 1·88 [1·24-2·86] for reteplase plus parenteral anticoagulants plus glycoprotein inhibitors). INTERPRETATION: Significant differences exist among various fibrinolytic regimens as reperfusion therapy in STEMI and alteplase (accelerated infusion), tenecteplase, and reteplase should be considered over streptokinase and non-accelerated infusion of alteplase. The addition of glycoprotein IIb or IIIa inhibitors to fibrinolytic therapy should be discouraged. FUNDING: None.
引用
- Jinatongthai P, Kongwatcharapong J, Foo CY, et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017. PMID: 28831992. doi:10.1016/S0140-6736(17)31441-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。